Shares of EverQuote (EVER) have gained 0.5% over the past four weeks to close the last trading session at $25.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.17 indicates a potential upside of 36.6%.The mean estimate comprises six short-term price targets with a standard deviation of $2.79. While the lowest estimate of $30.00 indicates a 19.9% increase from the current p ...

Shares of Omnicom (OMC) have gained 3.7% over the past four weeks to close the last trading session at $74.63, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.56 indicates a potential upside of 25.4%.The mean estimate comprises nine short-term price targets with a standard deviation of $13.43. While the lowest estimate of $78.00 indicates a 4.5% increase from the current pri ...

Core Viewpoint - Astrana Health, Inc. (ASTH) shows significant upside potential with a mean price target of $49.56, indicating a 97.3% increase from the current price of $25.12 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $36.00 to a high of $70.00, with a standard deviation of $12.39, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 43.3%, while the highest suggests a 178.7% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ASTH's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two estimates have been revised upward, leading to a 46.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - ASTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1: Stock Performance and Price Targets - Natural Gas Services (NGS) closed at $24.51, with a 27.3% gain over the past four weeks, and a mean price target of $36.25 suggests a 47.9% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $5.97, indicating variability; the lowest estimate of $32 suggests a 30.6% increase, while the highest target of $45 indicates an 83.6% surge [2] - A tight clustering of price targets, represented by a low standard deviation, indicates a high degree of agreement among analysts regarding the stock's price movement [9] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher for NGS, which correlates with potential stock price upside [11] - The Zacks Consensus Estimate for the current year has increased by 18.6% over the past month, with no negative revisions [12] - NGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has shown a significant price increase of 48.9% over the past four weeks, with a mean price target of $16.25 indicating a potential upside of 61.2% from the current price of $10.08 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $5.66, indicating variability among analysts; the lowest estimate is $8 (20.6% decline), while the highest is $30 (197.6% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Consensus - There is growing optimism among analysts regarding BCRX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 341.6% over the past month, with five estimates rising and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]

Core Viewpoint - Legend Biotech Corporation (LEGN) shows significant upside potential with a mean price target of $79.86, indicating a 135.2% increase from its current price of $33.96 [1] Price Targets - The average of 19 short-term price targets ranges from a low of $55 to a high of $95, with a standard deviation of $11.93, suggesting a variability in estimates [2] - The lowest estimate indicates a 62% increase, while the most optimistic estimate points to a 179.7% upside [2] Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank - LEGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - Enova International (ENVA) shares have increased by 1.8% over the past four weeks, closing at $97.88, with a mean price target of $127.71 indicating a potential upside of 30.5% [1] - The average price target from analysts ranges from a low of $109 to a high of $138, with a standard deviation of $10.80, suggesting a relatively high agreement among analysts regarding the stock's potential movement [2][9] - Analysts show strong agreement in revising earnings estimates higher for ENVA, which correlates with potential stock price increases, as indicated by a 0.3% increase in the Zacks Consensus Estimate for the current year [4][11][12] Group 2 - The Zacks Rank for ENVA is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets are often viewed as misleading, the direction implied by the consensus price target for ENVA appears to be a useful guide for potential price movement [7][10][11]